De-Risking the drug discovery process of Oncology and Metabolic diseases

Excellence: Vitala Technologies brings together Organ-on-Chip (OoC), hyperpolarized magnetic resonance spectroscopic imaging (HP MRSI), and advanced data analysis tools to provide a patented and revolutionary test for the monitoring of the efficacy in treatment of a new drug moving through the metabolic pathways of a cell.

This new methodology provides the opportunity to set preclinical drug testing strategies that are more effective, faster, cheaper, and reduce animal use.

The information obtained by this novel methodology will improve the future steps for drug candidates in advanced pre-clinical and clinical stages.

Vitala’s analysis allows defining and executing on pre-clinical testing strategies, increasing the speed of the drug discovery process, and reducing its costs.Impact: An increased accuracy in the early stages of the drug screening process will allow discarding inadequate pharmaceutical candidates before those reach the animal testing stage, reducing the number of animals used in the whole pre-clinical process.

Moreover, our objective is to de-risk and revolutionise the entire drug discovery process, decreasing the direct and indirect costs associated with the pre-clinical drug discovery pipeline with our real-time, non-destructive, highly sensitive technology.

Vitala’s impact will expand to later phases of drug discovery by preventing in-vitro and in vivo as well as human testing of drugs that in the absence of translatable models could have been deemed appropriate to proceed to later clinical trial stages.Implementation and team: Vitala is formed by a management team of professionals with complementary backgrounds in the fields of microfluidics, imaging technologies and business administration.

Vitala has already filled a PCT patent application and successfully completed an FTO, which gives our technology a green light to be exploited both in the EU and the USA with short and long term strategies in place.